RecruitingNCT07413757

CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)

Sponsor

AstraZeneca

Enrollment

590 participants

Start Date

Mar 2, 2026

Study Type

OBSERVATIONAL

Conditions

Non-small Cell Lung Cancer

Summary

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

Eligibility

Min Age: 18 Years

Inclusion Criteria24

Patient:
Provide informed consent
years or older
Diagnosed with stage IV NSCLC
Currently receiving or previously received 1L EGFR-TKI treatment
Without communication barrier
Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter
Physician:
Provide informed consent
Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
Holding the title of associate chief physician or higher
Patient:
Provide informed consent
years or older
Diagnosed with stage IV NSCLC
Currently receiving or previously received 1L EGFR-TKI treatment
Without communication barrier
Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter
Physician:
Provide informed consent
Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
Holding the title of attending physician or higher